Dyne Therapeutics reports FY2021 net loss $149.3M; cash to H2 2024; pipeline milestones outlined

Dyne Therapeutics, Inc.

Net loss of $149.3M for 2021 ($2.93/share) vs $59.4M in 2020; R&D spend $121.3M.
Cash, equivalents and securities $376.6M at Dec 31, 2021; cash runway into second half 2024.
FDA response for DYNE-251 IND in DMD expected Q2 2022; patient dosing in Phase 1/2 planned mid-2022.
Regulatory filings for DYNE-101 in DM1 in multiple countries planned Q2 2022 with mid-2022 trial start.
IND for DYNE-301 in FSHD expected in second half of 2022; board appointment of Carlo Incerti, M.D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.